{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:19:35Z","timestamp":1794608375449,"version":"4.9.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate the potential of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-SNA006 PET\/CT imaging as a noninvasive method for assessing immune cell infiltration and predicting treatment response in lung cancer patients undergoing immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      A prospective study enrolled 8 patients with histologically confirmed lung cancer who received first-line chemotherapy combined with anti\u2013PD-1\/PD-L1 immunotherapy.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-SNA006 PET\/CT imaging was performed before treatment. The primary endpoints analyzed the correlation between tumor SUVmax and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration, as well as associations of multiparametric imaging parameters (SUVmax, TBR, TLR, TSR, and TMR) with treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The SUVmax significantly correlated with stromal CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.8218,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0338) but not with intratumoral infiltration (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.5178,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05), indicating its stromal-specific association with immune activity. Among 8 patients, 6 achieved partial response and 2 stable diseases after 2 treatment cycles. Baseline blood CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, Ki67%, and PD-L1% showed no prognostic significance, nor did SUVmax correlate with posttreatment lesion reduction. In 24 lesions analyzed, TBR demonstrated the strongest correlation with lesion reduction (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.3178,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). ROC analysis further revealed that TBR had the highest diagnostic efficacy (AUC = 0.87) for predicting treatment response, with a sensitivity of 62.5% and specificity of 93.3% at a cutoff value of TBR &gt;2.120, and a sensitivity of 87.5% and specificity of 66.7% at TBR &gt;5.535.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-SNA006 PET\/CT provides valuable insights into immune cell infiltration and treatment response in lung cancer patients. The study highlights the potential of TBR as a prognostic biomarker and underscores the importance of integrating multiparametric imaging into clinical decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006098","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:07Z","timestamp":1756944007000},"page":"1152-1160","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["68Ga-NODAGA-SNA006 PET\/CT Imaging of Tumor CD8+ T-Cell Infiltration Predicts Immunotherapy Response in Lung Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Jinxin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Ruijin Hospital"},{"name":"Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine"},{"name":"Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Ruijin Hospital"},{"name":"Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine"},{"name":"Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangxi","family":"Hai","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Ruijin Hospital"},{"name":"Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine"},{"name":"Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Ruijin Hospital"},{"name":"Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine"},{"name":"Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-6232","authenticated-orcid":false,"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0177-8478","authenticated-orcid":false,"given":"Qiurui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Ruijin Hospital"},{"name":"Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine"},{"name":"Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"R1-20251114","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13578-025-01368-z","article-title":"The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes","volume":"15","author":"Shi","year":"2025","journal-title":"Cell Biosci"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12967-024-05940-y","article-title":"Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Jiang","year":"2024","journal-title":"J Transl Med"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1038\/s41598-025-91863-7","article-title":"A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3390\/biom10121695","article-title":"Nanobodies as versatile tool for multiscale imaging modalities","volume":"10","author":"Erreni","year":"2020","journal-title":"Biomolecules"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12951-021-00785-9","article-title":"ImmunoPET imaging of human CD8(+) T cells with novel (68)Ga-labeled nanobody companion diagnostic agents","volume":"19","author":"Zhao","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"R13-20251114","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1007\/s00259-022-05903-9","article-title":"Pilot study of a novel nanobody (68) Ga-NODAGA-SNA006 for instant PET imaging of CD8(+) T cells","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20251114","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00259-024-06999-x","article-title":"Human dose-escalation study of PET imaging CD8(+) T-cell infiltration in solid malignancies with [(68)Ga]Ga -NODAGA-SNA006","volume":"52","author":"Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","article-title":"(68)Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial","volume":"15","author":"Shen","year":"2024","journal-title":"Nat Commun"},{"key":"R18-20251114","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"R19-20251114","first-page":"720","article-title":"CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody","volume":"63","author":"Farwell","year":"2022","journal-title":"J Nucl Med"},{"key":"R20-20251114","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/1878-0261.13317","article-title":"Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab","volume":"17","author":"Spiliotaki","year":"2023","journal-title":"Mol Oncol"},{"key":"R21-20251114","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2967\/jnumed.124.267529","article-title":"Granzyme B PET\/CT imaging evaluates early response to immunotherapy in gastric cancer","volume":"65","author":"Liu","year":"2024","journal-title":"J Nucl Med"},{"key":"R22-20251114","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/pharmaceutics14020440","article-title":"Preclinical PET imaging of granzyme B shows promotion of immunological response following combination paclitaxel and immune checkpoint inhibition in triple negative breast cancer","volume":"14","author":"Napier","year":"2022","journal-title":"Pharmaceutics"},{"key":"R23-20251114","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","article-title":"The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition","volume":"8","author":"Williams","year":"2024","journal-title":"NPJ Precis Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:00:54Z","timestamp":1763125254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006098","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"2025-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}